Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.62 |
| ▸ | SRC | P12931 | 5/20 | 0.62 |
| ▸ | PRKCB | P05771 | 4/20 | 0.62 |
| ▸ | PRKCA | P17252 | 4/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.62 |
| ▸ | PRKCG | P05129 | 3/20 | 0.62 |
| ▸ | PRKCH | P24723 | 3/20 | 0.62 |
| ▸ | PRKCI | P41743 | 3/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.62 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.62 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30557775 | 1.00 | EGFR (0.62) | EGFRSRCPRKCBPRKCAPRKD3 | |
| SCHEMBL28772828 | 0.85 | EGFR (0.51) | EGFRSRCPRKCBPRKCAPRKD3 | |
| SCHEMBL17685237 | 0.84 | EGFR (0.64) | EGFRSRCPRKCBPRKCAPRKD3 | |
| SCHEMBL3259553 | 0.81 | KDM4E (0.64) | EGFRSRCPRKCBPRKCAPRKD3 | |
| Hydrochloric Acid SCHEMBL5138495 | 0.80 | KDM4E (0.62) | EGFRSRCPRKCBPRKCAPRKD3 | |
| Daph SCHEMBL11017 | 0.77 | EGFR (1.00) | EGFRSRCPRKCBPRKCAPRKD3 | |
| SCHEMBL27447702 | 0.76 | MAOA (0.49) | EGFRSRCPRKCBPRKCAPRKD3 | |
| SCHEMBL10733814 | 0.75 | MAPT (0.68) | EGFRMEN1MAPTKMT2ATDP1 | |
| SCHEMBL9006308 | 0.74 | MEN1 (0.58) | EGFRSRCPRKCBPRKCAPRKD3 | |
| SCHEMBL3259146 | 0.74 | EGFR (0.54) | EGFRSRCPRKCBPRKCAPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093656-B | Wear-resistant modified PVC material and synthesis process thereof | 广东铭宸工贸有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-115093656-A | Wear-resistant modified PVC material and synthesis process | 广东铭宸工贸有限公司 | 2022-09-23 | — | — | CN | claimed |
| EP-1806364-B1 | New anti-IGF-IR antibodies and their applications | PF MEDICAMENT (FR) | 2013-07-31 | — | — | EP | claimed |
| US-8361461-B2 | Anti-IGF-IR antibodies and uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2013-01-29 | — | — | US | claimed |
| US-20090265797-A1 | Novel Anti-IGF-IR Antibodies and Uses Thereof | PIERRE FABRE MEDICAMENT (FR) | 2009-10-22 | — | — | US | claimed |
| US-20080286198-A1 | Novel anti-IGF-IR antibodies and uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2008-11-20 | — | — | US | claimed |
| EP-1907426-A2 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2008-04-09 | — | — | EP | claimed |
| EP-1806364-A2 | New anti-IGF-IR antibodies and their applications | PIERRE FABRE MEDICAMENT (FR) | 2007-07-11 | — | — | EP | claimed |
| WO-2007012614-A2 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2007-02-01 | — | — | WO | claimed |
| US-20050281764-A1 | Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin | VOORHEES JOHN J | 2005-12-22 | — | — | US | claimed |
| US-20050084906-A1 | Novel anti-IGF-IR antibodies and uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-21 | — | — | US | claimed |
| EP-1461359-A2 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2004-09-29 | — | — | EP | claimed |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | US | claimed |
| WO-2003059951-A2 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2003-07-24 | — | — | WO | claimed |
| EP-1294349-A2 | USE OF EGF-R PROTEIN TYROSINE KINASE INHIBITORS FOR PREVENTING PHOTOAGING IN HUMAN SKIN | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001035899-A9 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-09-19 | — | — | WO | claimed |
| EP-1229925-A2 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-08-14 | — | — | EP | claimed |
| US-20020012641-A1 | Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-01-31 | — | — | US | claimed |
| WO-2002000183-A2 | USE OF EGF-R PROTEIN TYROSINE KINASE INHIBITORS FOR PREVENTING PHOTOAGING IN HUMAN SKIN | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2002-01-03 | — | — | WO | claimed |
| WO-2001035899-A2 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2001-05-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286198-A1 | Novel anti-IGF-IR antibodies and uses thereof | IGF1R, EGFR, IRS1 | EGFR 2/4885SRC 228/4885PRKCB 1609/4885 |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | EGFR, PTGFR, ERBB2 | EGFR 1/4885SRC 351/4885PRKCB 1231/4885 |
| US-20050084906-A1 | Novel anti-IGF-IR antibodies and uses thereof | IGF1R, EGFR, IRS1 | EGFR 2/4885SRC 228/4885PRKCB 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.